Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie dotyczące wspomagających leków przeciwpadaczkowych (ASM) Real World Evidence (RWE).

10 listopada 2026 zaktualizowane przez: Aziende Chimiche Riunite Angelini Francesco S.p.A

12-miesięczne prospektywne badanie obserwacyjne z udziałem dorosłych pacjentów z ogniskowymi napadami padaczkowymi leczonych wspomagająco ASM w rzeczywistych warunkach

The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

The aim of the study is to assess the effectiveness and safety of adjunctive therapy in a real-world setting of patients affected by focal-onset seizures who are eligible to start the treatment with ASM as adjunctive therapy according to the physician's judgment.

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

332

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Milan, Włochy, 20133
        • Fondazione IRCCS Istituto Neurologico "Carlo Besta" U.O. Epilettologia Clinica e Sperimentale - Centro di Medicina del Sonno

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 99 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka prawdopodobieństwa

Badana populacja

Adult patients with epilepsy having focal-onset seizures with or without secondary generalization not adequately controlled despite a history of treatment with at least 2 anti-seizure medications and who will meet all the inclusion and none of the exclusion study criteria.

The patients should be eligible to start a treatment with ASM as adjunctive therapy according to the physician's judgement, that must be clearly separated from the physician's decision to include the patient in the current study. The patients will be prospectively observed up to 12 months after having completed the related titration.

Opis

Inclusion Criteria:

  • Male and female patients of any ethnic origin ≥18 years old at baseline.
  • Patients with diagnosis of focal-onset seizures with or without secondary generalization.
  • Patients should have been eligible to start treatment with ASM as adjunctive therapy according to the physician's judgement prior to the inclusion.
  • Patients should have clinical history of treatment failure with at least 2 ASMs.
  • Patients using their seizure diary as part of their standard of care for at least 3 months prior to -the study entry (diary can be paper or electronic, filled in by patient and/or family members).
  • Written informed consent (including data privacy consent) signed by the patient, legal guardian, or legally authorized representative prior to entering the study in accordance with the ICH GCP guidelines

Exclusion Criteria:

  • Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC.
  • Progressive neurological disease, including degenerative CNS diseases and progressive tumors.
  • Patients with unstable psychiatric diagnosis that may confound participants' ability to participate in the study or that may prevent completion of the protocol-specified assessments (e.g., in the judgement of the Investigator, pose an appreciable risk for suicide, including suicidal behavior and ideation within 6 months prior to enrollment, current psychotic disorder, acute mania).
  • Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the Investigator could affect the participant's safety or interfere with study assessments.
  • Patients with substance abuse or dependence (except for caffeine and nicotine).
  • Patients participating in any pharmacological or nonpharmacological interventional study within 30 days prior to baseline.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: OTHER
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Adult patients with focal-onset seizures starting a treatment with ASM as adjunctive therapy

Adult patients having focal-onset seizures not adequately controlled despite a history of treatment with at least 2 ASM.

The patients should be eligible to start a treatment with ASM as adjunctive therapy.The patients will be prospectively observed up to 12 months after having completed the related titration.

ASM approved as adjunctive therapy

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in seizure frequency at 6 months of maintenance
Ramy czasowe: At 6 months of maintenance compared to baseline

The effectiveness of adjunctive ASM is measured as change in seizure frequency at 6 months of maintenance compared to baseline

At 6 months of maintenance compared to baseline

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in seizure frequency at 3, 9, 12 months of maintenance
Ramy czasowe: At 3, 9, 12 months of maintenance compared to baseline

The effectiveness of adjunctive ASM is measured as change in seizure frequency at 3, 9, 12 months of maintenance compared to baseline

At 3, 9, 12 months of maintenance compared to baseline
50, 75, 90 Percent Responder rate
Ramy czasowe: At 3, 6, 9, and 12 months of maintenance phase.

The effectiveness is measured as 50, 75, 90 Percent Responder rate

At 3, 6, 9, and 12 months of maintenance phase.
100 Percent Responder rate
Ramy czasowe: At 3, 6, 9, and 12 months of maintenance phase.

The effectiveness is measured as number/percentage of seizure free patients

At 3, 6, 9, and 12 months of maintenance phase.
Retention rate
Ramy czasowe: At 3, 6, 9, and 12 months of maintenance phase.

The effectiveness is measured as percentage of patients remaining in the study and on adjunctive therapy

At 3, 6, 9, and 12 months of maintenance phase.
Anxiety assessment
Ramy czasowe: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

The assessment is measured by means of the Generalized Anxiety Disorder (GAD-7) scale. Scoring GAD-7 Anxiety Severity is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21. 0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety.

At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.
Depression assessment
Ramy czasowe: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

The assessment is measured through the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) scale. This is a validated screening tool for depression in patients with epilepsy that consists of a 6- item questionnaire. NDDI-E scores greater than 15 were considered positive for depression, as this score was previously shown to have a specificity of 90%, sensitivity of 81%, and positive predictive value of 0.62 for a diagnosis of major depression.

At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.
Quality of life (QOL)
Ramy czasowe: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

The quality of life is measured by means the Quality Of Life In Epilepsy (QOLIE-31-P) questionnaire. This is a 38 questions survey of health-related quality of life for adults (18 years or older) with epilepsy. This version differs from the original QOLIE-31 (version 1) in the addition of questions about how much distress you feel about problems and worries related to epilepsy. This questionnaire should be completed only by the person who has epilepsy (not a relative or friend). Patients are asked to answer every question by circling the appropriate number (1, 2, 3...).

At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.
Cognitive assessment
Ramy czasowe: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

The assessment of perceived cognitive deficits is measured through the Perceived Deficits Questionnaire (PDQ-5). The PDQ-5 assesses cognitive dysfunction in people with depression. This patient-reported questionnaire includes five items measuring attention/concentration, retrospective memory, prospective memory, and planning/organization over the past four weeks. The total score ranges from 0 to 20; higher scores indicate greater perceived cognitive dysfunction.

At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.
Adverse events (AEs)
Ramy czasowe: Through study completion, an average of 1 year

Number of Adverse events (AEs) occurred (including AEs of special interest as Drug Reaction with Eosinophilia and Systemic Symptoms, rash/hypersensitivity, etc.).

Through study completion, an average of 1 year

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

2 maja 2023

Zakończenie podstawowe (Rzeczywisty)

30 września 2025

Ukończenie studiów (Rzeczywisty)

30 września 2025

Daty rejestracji na studia

Pierwszy przesłany

21 marca 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

17 maja 2023

Pierwszy wysłany (Rzeczywisty)

19 maja 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj